Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AUROPHARMA.NS
Strong BuyPremium GrowerAurobindo Pharma Limited · Healthcare · India · $10.3B · Avg Vol: $17M/d
91
StockRankGet insider-trade alerts
Q
67
V
44
M
80
P/E (TTM)
26.0x
ROE
9.2%
D/E
0.2x
Dividend %
0.2%
COMPANY DESCRIPTION
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 246.2B | 287.0B | 313.8B | 333.8B | 10.7% | 350.5B | 397.1B | 439.7B | 14.8% |
| EPS (INR) | 32.90 | 54.16 | 59.81 | 60.34 | 22.4% | 65.53 | 78.71 | 91.80 | 23.3% |
| Shares | 585.9M | 585.9M | 580.8M | 580.8M | -0.9% | 575.4M | — | — | — |
| Debt | 52.9B | 66.5B | 82.6B | 80.7B | 15.2% | 81.0B | — | — | — |
| Equity | 268.4B | 298.4B | 326.5B | 378.9B | 12.2% | — | — | — | — |
| Op CF | 23.9B | 24.3B | 39.2B | 55.3B | 32.3% | 55.5B | — | — | — |
| Inv CF | -39.8B | -42.6B | -18.8B | -34.6B | — | — | — | — | — |
| Fin CF | 18.1B | 8.0B | 1.2B | -12.7B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+6.8%
SMA 50SMA 200
Close
$17.80
RSI (14)
62.7
52W High
$17.99
From 52W High
1.0%
SCORE BREAKDOWN
Quality
67
ROIC
13.5%79.6
ROE
9.2%67.8
GP/Assets
35.1%71.1
Op. Margin
15.2%75.4
FCF/Assets
4.1%66.4
Piotroski
668.8
Int. Cover
15.5x68.4
D/E Ratio
0.21x49.0
Current Ratio
1.81x34.8
Value
44
P/E (TTM)
26.0x46.7
EV/EBITDA
13.6x54.0
P/FCF
40.3x36.0
P/B
2.6x52.1
P/S
2.8x58.7
Div Yield
0.2%6.0
Momentum
80
52W High %
99%99.0
RS 6M
36%87.4
SMA 50/200
1.16x84.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+42%49.9
Q Growth
25%59.0
FUNDAMENTALS
Market Cap
$10.3B
P/E (Forward)
18.3x
Gross Margin
58.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AUROPHARMA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AUROPHARMA.NS | Aurobindo Pharma Limited(you) | $10.3B | 91 | Strong Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| GLENMARK.NS | Glenmark Pharmaceuticals Limited | $7.4B | 94 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%